Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Patrick M. Forde, Jonathan Spicer, Shun Lü, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 1973-1985
Open Access | Times Cited: 1680

Showing 26-50 of 1680 citing articles:

Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Zhenyi Niu, Runsen Jin, Yan Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 95
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
Marie Wislez, Julien Mazières, A. Lavolé, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 10, pp. e005636-e005636
Open Access | Times Cited: 88
Targeting immunogenic cell stress and death for cancer therapy
Lorenzo Galluzzi, Emma Guilbaud, Darby Schmidt, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 6, pp. 445-460
Open Access | Times Cited: 82
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
Jarushka Naidoo, Catherine J. Murphy, Michael B. Atkins, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e006398-e006398
Open Access | Times Cited: 76
Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
Xiaoyan Sun, Weiran Liu, Leina Sun, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 11, pp. e005531-e005531
Open Access | Times Cited: 74
Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Julie S. Deutsch, Ashley Cimino‐Mathews, Elizabeth D. Thompson, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 218-228
Open Access | Times Cited: 73
Chemo-Immunotherapy: A New Trend in Cancer Treatment
Christian Sordo‐Bahamonde, Seila Lorenzo‐Herrero, Ana Pilar González-Rodríguez, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2912-2912
Open Access | Times Cited: 68
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
Jason J. Luke, Sarina A. Piha‐Paul, Theresa Medina, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 13, pp. 2435-2444
Open Access | Times Cited: 67
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
Lavanya Sivapalan, Joseph C. Murray, Jenna VanLiere Canzoniero, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005924-e005924
Open Access | Times Cited: 66
Neoadjuvant Chemoimmunotherapy for NSCLC
Mark Sorin, Connor Prosty, Louis Ghaleb, et al.
JAMA Oncology (2024) Vol. 10, Iss. 5, pp. 621-621
Open Access | Times Cited: 65
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722
Tony Mok, Kazuhiko Nakagawa, Keunchil Park, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 11, pp. 1252-1264
Open Access | Times Cited: 63
Immunosurveillance in clinical cancer management
Guido Kroemer, Timothy A. Chan, Alexander M.M. Eggermont, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 74, Iss. 2, pp. 187-202
Open Access | Times Cited: 62
Cancer metastasis: Molecular mechanisms and clinical perspectives
Sameer Ullah Khan, Kaneez Fatima, Fayaz Malik, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108522-108522
Closed Access | Times Cited: 60
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Tina Cascone, Gozde Kar, Jonathan Spicer, et al.
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2394-2411
Open Access | Times Cited: 59
Emerging evidence and treatment paradigm of non-small cell lung cancer
Si‐Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 58
Novel targets for immune-checkpoint inhibition in cancer
Maxime Borgeaud, José Luís Sandoval, Michel Obéid, et al.
Cancer Treatment Reviews (2023) Vol. 120, pp. 102614-102614
Open Access | Times Cited: 53
Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer
Jie Lei, Jinbo Zhao, Li Gong, et al.
JAMA Oncology (2023) Vol. 9, Iss. 10, pp. 1348-1348
Open Access | Times Cited: 52
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
James Huang, Raymond U. Osarogiagbon, Dorothy J. Giroux, et al.
Journal of Thoracic Oncology (2023) Vol. 19, Iss. 5, pp. 766-785
Open Access | Times Cited: 52
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 4, pp. 705-710
Open Access | Times Cited: 49
The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer
Tarek Taifour, Sherif Samer Attalla, Dongmei Zuo, et al.
Immunity (2023) Vol. 56, Iss. 12, pp. 2755-2772.e8
Open Access | Times Cited: 49
Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Ronan J. Kelly, Blair V. Landon, Ali H. Zaidi, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1023-1034
Open Access | Times Cited: 32
Neoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer
Giuseppe Luigi Banna, Mohd Ali Hassan, Alessio Signori, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e246837-e246837
Open Access | Times Cited: 29
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
Martin Schüler, Kristof Cuppens, Till Plönes, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1602-1611
Open Access | Times Cited: 29
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Jacobi Hines, Robert B. Cameron, Alessandra Esposito, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 7, pp. 1108-1116
Open Access | Times Cited: 27

Scroll to top